Angiopoietin-like 3 proteins have emerged as a new class of lipid metabolism modulators which may serve as a potential novel therapeutic target for reducing plasma lipoprotein and treatment of metabolic syndrome. This evidence concerns the gene ANGPTL3 and metabolic syndrome.